netFormulary NHS
Lancashire and South Cumbria
Formulary
 Search
 Results

Looking for Semaglutide found 17 matches

Formulary items 5 matches
   
Open monograph to display formulary status BNF Category
  Semaglutide  (Ozempic®) Endocrine system - GLP1 agonists - 06.01.02.03
  Semaglutide  (Rybelsus®) Endocrine system - GLP1 agonists - 06.01.02.03
  Semaglutide  (Wegovy®) Central nervous system - Anti-obesity drugs acting on the gastro-intestinal tract - 04.05.01
  Semaglutide  (Wegovy®) Endocrine system - GLP1 agonists - 06.01.02.03
  Tirzepatide Endocrine system - GLP1 agonists - 06.01.02.03
 


Linkslink in drug section Link to Drug Section link in subsection Link to document
link in drug section Medicines Matters no 39 Rybelsus® (oral semaglutide): risk of medication error due to introduction of new formulation with increased bioavailability (06.01.02.03)
link in drug section MHRA drug safety update: Rybelsus ® (semaglutide tablets): transition to new formulation and risk of medication error (06.01.02.03)
link in drug section MHRA: Ozempic▼(semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products (06.01.02.03)
link in drug section MHRA: Ozempic▼(semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products (06.01.02.03)
link in drug section MHRA: Ozempic▼(semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products (04.05.01)
link in drug section MHRA: Semaglutide (Wegovy, Ozempic and Rybelsus): risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) (06.01.02.03)
link in drug section MHRA: Semaglutide (Wegovy, Ozempic and Rybelsus): risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) (04.05.01)
link in drug section MHRA: Semaglutide (Wegovy, Ozempic and Rybelsus): risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) (06.01.02.03)
link in drug section MHRA: Semaglutide (Wegovy, Ozempic and Rybelsus): risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) (06.01.02.03)
link in drug section NICE TA875: Semaglutide for managing overweight and obesity (06.01.02.03)
link in drug section NICE TA875: Semaglutide for managing overweight and obesity (04.05.01)
link in drug section Rybelsus® (oral semaglutide): risk of medication error due to introduction of new formulation with increased bioavailability (06.01.02.03)




Document Library Items Found

 
netFormulary